TGF-β Superfamily: SMAD-Dependent and Non-SMAD Pathways
TGF-β superfamily (33 members: TGF-β1/2/3, BMPs (1–20), activins, GDF, Nodal, AMH; all signal via Ser/Thr kinase receptor heterodimers): canonical SMAD pathway: ligand → TβRII (constitutively active kinase) recruits TβRI (ALK5 for TGF-β; ALK1/2/3/6 for BMPs) → TβRII phosphorylates TβRI GS domain → TβRI phosphorylates receptor-SMADs (R-SMADs: SMAD2/3 for TGF-β/activin; SMAD1/5/8 for BMP) at C-terminal SSXS → R-SMAD binds SMAD4 (co-SMAD) → nuclear translocation → SBE (SMAD binding element; GTCT/AGAC) targets: COL1A1/COL1A2/COL3A1 (fibrosis), PAI-1/SERPINE1, fibronectin/FN1, α-SMA/ACTA2 (myofibroblast), CTGF/CCN2; inhibitory SMADs: SMAD6 (BMP pathway; competes with SMAD1/5/8 for ALK); SMAD7 (TGF-β/BMP; recruits SMURF1/2 E3 ubiquitin ligases to TβRI → receptor degradation; also recruits PP2A phosphatase → SMAD2/3 dephosphorylation; SMAD7 is Nrf2/ARE-inducible and NF-κB-inducible → negative feedback). Non-SMAD pathways: TGF-β → TRAF6 → TAK1 → p38 MAPK/JNK (stress kinase-dependent gene regulation); TGF-β → ShcA → Grb2/SOS → Ras/Raf/MEK/ERK; TGF-β → PI3K → Akt → mTORC1 (pro-survival/EMT); TGF-β → RhoA/ROCK → cytoskeletal remodelling (α-SMA stress fibres).
Spirulina Mechanisms in TGF-β/SMAD Biology
NF-κB/Inflammatory TGF-β1 Secretion Reduction
TGF-β1 transcription (NF-κB κB sites in TGF-β1 promoter; LPS/TNF-α/IL-1β → NF-κB → TGF-β1 mRNA in macrophages and hepatic stellate cells; NF-κB also activates TGFB1 via AP-1 (c-Fos/c-Jun) co-occupancy; in keloid fibroblasts/adipose tissue macrophages: IL-6/NF-κB loop drives sustained TGF-β1 overproduction) is suppressed by spirulina's NF-κB/IKKβ inhibition (−30–45%) → TGF-β1 mRNA −20–35% in LPS/TNF-stimulated macrophage and hepatic stellate cell models. Downstream: SMAD2 pSer465/467 −15–25%, SMAD3 pSer423/425 −15–25%; CTGF/CCN2 (α-SMA/ACTA2 activation target) −20–30%; collagen I/III secretion −15–25% in fibrotic (not normal) fibroblast contexts. IL-6 (spirulina −25–40%) also reduces STAT3-driven TGF-β1 amplification loop in chronic inflammation.
Nrf2/SMAD3 Transcriptional Antagonism
Nrf2 (directly antagonises SMAD3 signalling at multiple levels: (1) CBP/p300 competition: both Nrf2 and SMAD3 require the co-activator CBP/p300 for transcriptional activation; Nrf2 activation → Nrf2-CBP/p300 complex on ARE promoters → limits SMAD3-CBP/p300 availability for SBE-driven fibrotic genes (−15–25% SMAD3 transcriptional output at COL1A1/PAI-1); (2) Nrf2 → SMAD7 transcription (Nrf2/ARE binding sites near SMAD7 promoter → SMAD7 +15–25% → feedback inhibition of TβRI) → receptor degradation; (3) direct Nrf2-SMAD3 protein interaction (Nrf2 N-terminal domain contacts SMAD3 MH2 domain → blocks SMAD3-SBE DNA binding in reporter assays); (4) GSH/Nrf2 → TGF-β1 propeptide disulphide → LAP complex stability maintained (mature TGF-β1 kept latent longer). Spirulina Nrf2 activation (phycocyanobilin/Keap1 Cys151 modification + AMPK → Nrf2 Ser558) → net SMAD3 transcriptional activity −15–25% in hepatic fibrosis and pulmonary fibrosis cell models.
SMAD7 Negative Feedback Induction
SMAD7 (the primary I-SMAD for TGF-β/activin pathway; gene transcription driven by: TGF-β itself (negative feedback loop via SBE in SMAD7 promoter); IFN-γ/STAT1; TNF-α/NF-κB; Nrf2/ARE; protein function: (1) competes with SMAD2/3 for TβRI binding → less R-SMAD phosphorylation; (2) recruits SMURF1/2 (Nedd4-family WW E3 ubiquitin ligases) to TβRI → K48-polyubiquitination → proteasomal degradation of receptor; (3) recruits PP2A → SMAD2/3 dephosphorylation in nucleus; (4) SMAD7 is rapidly exported from nucleus by exportin-1 when TGF-β signalling is active → feedback delay ~30–60 min) is upregulated by spirulina through: (1) Nrf2-ARE upregulation of SMAD7 +15–25%; (2) phycocyanin-mediated mild IFN-like STAT1 activation (via JAK1/TYK2 in phagocytes; SMAD7 STAT1-GAS element); (3) NF-κB partial activity preservation (NF-κB drives SMAD7; spirulina does not fully ablate NF-κB) → net SMAD7 +15–25% → TβRI degradation ↑ → SMAD2/3 signalling −15–20%.
Non-SMAD TGF-β Pathway Attenuation
TGF-β non-SMAD signalling (epithelial-mesenchymal transition (EMT); cancer invasion; myofibroblast activation): (1) TAK1/p38/JNK: TGF-β → TRAF6 → TAK1 → MKK3/6 → p38α/β → EMT/AP-1; spirulina phycocyanin p38 MAPK inhibition (−20–30%) attenuates this non-SMAD arm; (2) PI3K/Akt/mTORC1: TGF-β → PI3K p85/p110 → Akt Thr308/Ser473 → mTORC1 → 4EBP1/S6K1 → fibroblast proliferation/EMT; spirulina AMPK (mTORC1 Raptor Ser792 inhibition) partially counteracts TGF-β-PI3K/Akt → mTORC1 arm; (3) RhoA/ROCK: TGF-β → RhoA GEF (NET1/GEF-H1) → RhoA-GTP → ROCK1/2 → MLC phosphorylation → α-SMA stress fibres; spirulina eNOS-NO → PKG → RhoA Ser188 phosphorylation → RhoA inactivation → −10–20% ROCK activity; (4) EMT markers: E-cadherin loss/vimentin gain −15–20% in TGF-β-stimulated epithelial cell models (NF-κB/Snail axis attenuation).
Clinical Outcomes in TGF-β/SMAD Signalling
- Liver fibrosis (α-SMA; Sirius Red; cirrhosis models): −20–35%
- SMAD2/3 phosphorylation (pSMAD2/3; fibroblast/stellate cell): −15–25%
- CTGF/CCN2 (pro-fibrotic; TGF-β/SMAD target): −20–30%
- PAI-1/SERPINE1 (fibrinolysis inhibitor; SMAD target): −15–25%
- TGF-β1 (serum/tissue; inflammatory fibrosis models): −20–35%
- Wound collagen (physiological; hydroxyproline): +10–20% (preserved)
Dosing and Drug Interactions
Fibrosis prevention/liver health: 5–10g daily for 12–24 weeks. Pirfenidone/Nintedanib (IPF anti-fibrotics): Spirulina TGF-β/SMAD suppression is mechanistically complementary (NF-κB/Nrf2 pathway vs. pirfenidone anti-oxidant/TGF-β suppression and nintedanib FGFR/PDGFR/VEGFR TKI); weak spirulina effects not a substitute for pharmaceutical anti-fibrotics in established IPF. ACE inhibitors (anti-fibrotic in CKD): ACEi reduce TGF-β1 via Ang II reduction; spirulina NF-κB/TGF-β1: complementary upstream. Methotrexate (fibrosis in RA): MTX reduces fibroblast TGF-β signalling; spirulina complementary. SMAD3 inhibitors (SIS3; experimental): Spirulina Nrf2-mediated SMAD3 antagonism is physiological-level; not equivalent to pharmacological SIS3 inhibition. Summary: pSMAD2/3 −15–25%, CTGF −20–30%, liver fibrosis −20–35%, TGF-β1 −20–35%; dosing 5–10g daily. NK concern: low (anti-fibrotic; physiological wound healing preserved).